Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06086288 | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)(PANDORA) | not yet recruiting | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER |
| 1 |
| Oct 17, 2023 |
| clinicaltrials |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | not yet recruiting | Phase 2 | 54 | Jin LiOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT05988697 | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | not yet recruiting | — | 36 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06079723 | A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06076772 | Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients | not yet recruiting | — | 54 | Assiut UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06066931 | Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE | not yet recruiting | N/A | 150 | Kuban State Medical UniversityOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT06075238 | Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | not yet recruiting | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05540275 | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma | not yet recruiting | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070246 | Navigating the Clinical Research Process for Lymphoma | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070259 | Insights Into Participating in Studies for Bone Cancer | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070272 | Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070285 | Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067776 | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | not yet recruiting | Phase 1 | 36 | Jonathan RiessOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT06062485 | Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06062589 | AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer | not yet recruiting | — | 18 | Peking University Third HospitalOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06063070 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06039982 | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer | not yet recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06053996 | Hepatopulmonary Radio-sterilization With Immunotherapy(TROS-8) | not yet recruiting | N/A | 44 | Sheba Medical CenterOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055114 | Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age | not yet recruiting | — | 300 | Lin YuanOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06049485 | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | not yet recruiting | Phase 4 | 62 | SciClone PharmaceuticalsINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT06041490 | Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | not yet recruiting | Phase 2 | 88 | Peking Union Medical College HospitalOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06039033 | Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06039046 | Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06039891 | Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 55 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2023 | clinicaltrials |
| NCT05318794 | Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer(SPECTRA) | not yet recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06032728 | Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | not yet recruiting | N/A | 488 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT06035133 | Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy | not yet recruiting | N/A | 213 | Tang-Du HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03865277 | Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging(INDIRA-MISO) | not yet recruiting | Phase 2 | 276 | Technische Universität DresdenOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06029465 | Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06029478 | Understanding Engagement Trends in Chondrosarcoma Clinical Trials | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT06022341 | MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies(MOZART) | not yet recruiting | N/A | 120 | University Hospital, AngersOTHER_GOV | 0 | Sep 1, 2023 | clinicaltrials |
| NCT06014944 | Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody(PMMR/MSS) | not yet recruiting | Phase 2 | 30 | Changhai HospitalOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT06017063 | Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields(COCOON) | not yet recruiting | N/A | 275 | University Hospital TuebingenOTHER | 0 | Aug 30, 2023 | clinicaltrials |
| NCT06015113 | Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis | not yet recruiting | N/A | 20 | Xi'an International Medical Center HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06016413 | Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05914610 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 3 | 100 | Fujian Medical UniversityOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT06009029 | SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | not yet recruiting | Phase 2 | 96 | Peking University Third HospitalOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT06009510 | Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06009549 | A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05985707 | KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | not yet recruiting | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998798 | Revealing Engagement Patterns Among Endometrial Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998811 | Insights Into Participating in Studies for Uterine Cancer | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 18, 2023source: clinicaltrials